Advertisement

Journal of Chemical Crystallography

, Volume 35, Issue 3, pp 227–232 | Cite as

Synthesis and crystal structures of cis- and trans-1-(3′-N, N-dimethylthiocarbamoyl-4′-methoxy)-2-(3″, 4″, 5″trimethoxyphenyl) ethene

  • Daniel A. Ramirez
  • Jianxing Zhang
  • Kevin Klausmeyer
  • Robert R. KaneEmail author
Article

Abstract

The combretastatin A-4 analogue cis-1-(3′-N,N-dimethylthiocarbamoyl-4′-methoxy)-2-(3″,4″, 5″-trimethoxyphenyl) ethene (1) and its trans stereoisomer (2) were synthesized. The molecular structures of these compounds were obtained by single-crystal X-ray diffraction. Crystallization of 1 occurs in the centrosymmetric monoclinic space group C2/c (No. 15) with a = 21.468(5), b = 7.932(1), c = 23.949(3); and β = 100.75(1) and Z = 8. Crystallization of 2 occurs in the centrosymmetric monoclinic space group P21/n (No. 14) with a = 11.7825(7), b = 11.562(1), c = 14.911(1) and β = 93.294(6); and Z = 4. Details of the synthesis and the structural characterization of the title compounds are presented and discussed.

Keywords

combretastatin stilbene thiocarbamate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Burrows, F.J.; Thorpe, P.E. Pharmacol. Ther. 1994, 64(1), 155–174.CrossRefGoogle Scholar
  2. 2.
    Siemann, D.W.; Chaplin, D.J.; Horsman, M.R. Cancer 2004, 100(12), 2491–2499.CrossRefGoogle Scholar
  3. 3.
    Pettit, G.R.; Cragg, G.M.; Herald, D.L.; Schmidt, J.M.; Lohavanijaya, P. Can. J. Chem. 1982, 60, 1374–1376.CrossRefGoogle Scholar
  4. 4.
    Pettit, G.R.; Cragg, G.M.; Singh, S.B. J. Nat. Prod. 1987, 50, 386–391.CrossRefGoogle Scholar
  5. 5.
    Pettit, G.R.; Lippert, J.W., III; Herald, D.C. J. Org. Chem. 2000, 65, 7438–7444.CrossRefGoogle Scholar
  6. 6.
    Hamel, E.; Lin, C.M. Biochem. Pharmacol. 1983, 32, 3864–3867.CrossRefGoogle Scholar
  7. 7.
    Pettit, G.R.; Rhodes, M.R. Anticancer Drug Des. 1998, 13, 183–191.Google Scholar
  8. 8.
    Molema, G. Pharm. Res. 2002, 19(9), 1251–1258.CrossRefGoogle Scholar
  9. 9.
    Ohsumi, K.; Nakagawa, R.; Fukuda, Y.; Hatanaka, T.; Morinaga, Y.; Nihei, Y.; Ohishi, K.; Suga, Y.; Akiyama, Y.; Tsuji, T. J. Med. Chem. 1998, 41(16), 3022–3032.CrossRefGoogle Scholar
  10. 10.
    Hori, K.; Saito, S.; Nihei, Y.; Suzuki, M.; Sato Y. Jpn. J. Cancer Res. 1999, 90, 1026–1038.CrossRefGoogle Scholar
  11. 11.
    Sheldrick, G.M. SHELXTL, version 6.12; Bruker AXS, Inc.: Madison, WI, 2001.Google Scholar
  12. 12.
    Newman, M.S.; Karnes, H.A. J. Org. Chem. 1966, 31(12), 3980–3984.CrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Daniel A. Ramirez
    • 1
  • Jianxing Zhang
    • 1
  • Kevin Klausmeyer
    • 1
  • Robert R. Kane
    • 1
    Email author
  1. 1.Department of Chemistry and Biochemistry and the Center for Drug DiscoveryBaylor UniversityWaco

Personalised recommendations